Welcome to our dedicated page for QSCREEN AI news (Ticker: PMEDF), a resource for investors and traders seeking the latest updates and insights on QSCREEN AI stock.
QScreen AI Inc. develops artificial-intelligence health screening technology for clinical, correctional, occupational, and institutional settings. Company news centers on the QAI Platform, which combines physiological signals from a standard camera, passive voice analysis, and structured clinical intake workflows to support real-time screening and documented intake outputs.
Recurring updates cover platform integration, internal validation work, patent activity, commercialization efforts in North American institutional and workforce markets, strategic advisory and contractor relationships, and financing actions tied to deployment and working capital. The company also reports on clinical instruments used within its intake workflows, including CIWA-Ar, COWS, and C-SSRS.
QScreen AI (PMEDF) will settle $681,000 of debt owed to certain directors and officers by issuing approximately 9.73 million common shares at a deemed price of $0.07 per share. The price reflects a premium of about 180% to the $0.025 CSE closing price on September 18, 2026, and about 40% to the $0.05 unit price of a recent private placement. The transaction removes $681,000 of liabilities without cash outlay, which the company says helps preserve funds for commercialization in the United States, Mexico and the European Union. The deal is a related party transaction under MI 61-101, but QScreen relies on valuation and minority approval exemptions as the fair market value is under 25% of its market capitalization. The new shares will be subject to a four‑month‑plus‑one‑day statutory hold period.
QScreen AI (PMEDF) has closed the final tranche of its previously announced non-brokered private placement through the issuance of 6,153,256 units at $0.05 per unit, raising gross proceeds of approximately $307,662.80.
Each unit includes one common share and one-half common share purchase warrant. Each whole warrant allows the holder to acquire one additional common share at an exercise price of $0.07 for 36 months from issuance, subject to previously disclosed acceleration provisions. Net proceeds are expected to fund commercialization, business development, technology advancement, strategic market expansion and general working capital. All securities carry a four-month-and-one-day statutory hold period.
QScreen AI (CSE: QAI, OTC: PMEDF, FSE: 3QP) announced completion of its tiered screening architecture, now fully implemented in its browser-based readiness and impairment screening platform. The system uses a ~90-second first-stage gate on standard laptop or tablet webcams, escalating only ambiguous results to an extended assessment measuring smooth-pursuit eye tracking, response inhibition, and sustained attention.
According to the company, all steps, escalation outcomes, and final human decisions are logged and displayed in a supervisor console, with safety-critical signals routed directly to a person. The architecture is being demonstrated to a growing institutional pipeline in the southeastern United States and supports a commercial model based on workforce coverage site licensing.
QScreen AI (CSE: QAI, OTC Pink: PMEDF, FSE: 3QP) reports that the US Patent and Trademark Office granted US Patent No. 12,640,164 on May 26, 2026, covering its core impairment-detection method from a single camera on standard, already-deployed hardware.
This second US patent complements US 11,670,323 B2, which covers multi-camera and audio-based approaches, giving QScreen method protection across single- and multi-camera deployments. The patented platform analyzes physiological, acoustic and behavioral signals and underpins ongoing commercial outreach in US and Canadian correctional health, defense, rail and logistics markets, where a first signed evaluation agreement remains the near-term milestone.
QScreen AI (OTC:PMEDF) elected to move from quarterly to semi-annual financial reporting under Canadian CBO 51-933 for eligible venture issuers. The company aims to reduce administrative and financial reporting burden and redirect resources toward core business objectives.
The first period without quarterly disclosure is the three months ended April 30, 2026. The next scheduled filing will cover the six-month interim period ending July 31, 2026. QScreen AI will continue to file audited annual and six-month interim financial statements with MD&A and comply with all continuous disclosure requirements, including reporting material changes.
QScreen AI (OTC: PMEDF) closed the first tranche of its non-brokered private placement, issuing 4,876,400 units at $0.05 for gross proceeds of about $243,820.
Each unit includes one share and half a warrant exercisable at $0.07 for 36 months. Funds will support commercialization, business development, technology advancement, market expansion and working capital.
QScreen AI (OTC Pink: PMEDF) will hold a five-city investor roadshow across Central Europe from June 1–5, 2026, visiting Munich, Ljubljana, Budapest, Bratislava, and Vienna.
Recent milestones include integrating passive voice analysis, surpassing 720,000 physiological scans, adding senior advisors, and expanding a patent-backed, multi-modal screening platform.
QScreen AI (OTC: PMEDF) appointed retired Lieutenant General Michael S. Groen, former Director of the Pentagon’s Joint Artificial Intelligence Center, to its Advisory Board after a live platform demonstration on May 11, 2026.
The proprietary physiological AI screening platform analyzes 34 physiological signals and 13 clinical instruments via standard cameras and voice to identify probable impairment patterns, substance classes, and certain withdrawal states. Groen, alongside Global Frontier Advisors, is expected to support commercialization across correctional health, national defense, transportation, and federal security markets in North America.
QScreen AI (OTC: PMEDF) announced integration of a passive voice analysis engine into its multi-signal screening platform on May 6, 2026. The system now reads physiological, acoustic, and behavioral signals simultaneously using existing device microphones and camera data, with individualized longitudinal baselining and no added hardware or workflow changes.
The platform measures voice features such as response latency, speech rate, vocal tremor and pitch against each person’s prior baseline, and is positioned for correctional intake, pre-shift fitness-for-duty screening and addiction rehabilitation deployments.
QScreen AI (OTC: PMEDF) reported internal validation of its correctional intake platform across 65 calibrated clinical scenarios, validating nine instruments versus published thresholds. Key results include 100% sensitivity and specificity for Columbia C-SSRS suicide risk and CIWA-Ar/COWS withdrawal, plus an active 60-day pilot plan and no specialized hardware required for deployment.